Skip to content

Study Details

A study to see if an investigational study drug, nerandomilast, helps people with SARD-ILD

(IRB#: IRB_00190779)

The purpose of this study is to investigate whether a drug called nerandomilast works to help people with SARD-ILD improve their lung function. You will be in the study for about 7.5 months. During this time, you will visit the study site 8 times.

I AM INTERESTED

  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • 1. Participant has SARD-ILD
  • 2. Patients 18 years old

Exclusion Criteria

  • 1. Acute ILD exacerbation within 3 months prior to Visit 1
  • 2. Patients with active TB
  • 3. Patients with underlying liver cirrhosis
  • 4. Women who are pregnant, breastfeeding, or who plan to become pregnant while in the trial

Will I be paid for my time?

Yes

For more information contact:

Heather Hammerschmidt

heather.hammerschmidt@hsc.utah.edu

  801-581-5811

IRB#: IRB_00190779

PI: Mary Beth Scholand

Department: PULMONARY

Approval Date: 2026-03-18 06:00:00

Specialties: Pulmonary

Last Updated: 6/8/23